Immunotherapy Brings Hope to Liver Cancer Patients, but One-Third Who Stop Treatment Face Rising Regret

Immunotherapy has rewritten the story of advanced liver cancer. For patients with hepatocellular carcinoma, the most common form of primary liver cancer and one of the deadliest malignancies worldwide, the arrival of combination regimens that pair immune checkpoint inhibitors with targeted agents has delivered survival gains that older therapies could not match. Yet a new study from Taiwan suggests that the clinical statistics tell only part of the story. Behind every tumor scan lies a patient weighing hope against hardship, and the psychological trajectory of treatment may matter as much as the radiological one. Researchers reporting in Supportive Care in Cancer have now tracked, in unusual detail, how hope, fatigue, quality of life and decision regret evolve during the first months of first-line immunotherapy-targeted therapy for this disease.

The investigation, led by Huei-Shiuan Wang and Tsai-Wei Huang of Taipei Medical University together with Ann-Lii Cheng of the National Taiwan University Cancer Center and Jin-Hua Chen of National Taiwan University, took a deliberately hybrid approach. Between December 2022 and October 2023, the team enrolled 33 patients who were beginning first-line immunotherapy-targeted combination treatment at a major Taiwanese medical center. Rather than relying on a single questionnaire at a single moment, the researchers measured patient-reported outcomes across six treatment cycles using validated instruments, including the EQ-5D health utility index, the Brief Fatigue Inventory, the Herth Hope Index and a standardized decision regret scale. In parallel, every participant completed an in-depth qualitative interview. The quantitative and qualitative strands were then integrated through joint display analysis, a mixed-methods technique designed to reveal where measured data and lived experience converge and where they diverge.

The headline finding is a tale of two trajectories. Twenty-one patients, or 63.6 percent of the cohort, completed all six cycles of treatment. Among these completers, patient-reported outcomes remained remarkably stable: quality of life held steady, fatigue stayed manageable, and decision regret remained low. In other words, for the majority of patients who could tolerate the regimen, the treatment experience was not the ordeal that the word chemotherapy often conjures. This stability is clinically meaningful because it aligns with earlier randomized evidence from the IMbrave150 trial, which demonstrated that atezolizumab plus bevacizumab preserved quality of life better than the previous standard of care, sorafenib. The Taiwanese data now extend that picture into routine clinical practice, showing that patients who stay on therapy tend to sustain their functional well-being over successive cycles.

The picture darkens considerably for the twelve patients, 36.4 percent of the cohort, who discontinued treatment before completing six cycles. These patients experienced a measurably faster decline in EQ-5D utility scores, with a statistical interaction of B = -0.169 per cycle (p = .007), indicating that each additional cycle widened the gap between the two groups. Their regret scores also climbed more steeply, rising by 9.58 points on average (p = .051, an effect size of d = 0.50), a difference that reached statistical significance in the between-group comparison (p = .042) even though the within-group change itself fell just short of conventional significance thresholds. Discontinuers also reported worse fatigue than completers. The authors interpret discontinuation not merely as a clinical event but as a psychologically vulnerable transition, a moment when the treatment narrative a patient has been living by suddenly changes course.

Perhaps the most sobering result concerns hope. Using the Herth Hope Index, a widely used instrument rooted in Snyder’s hope theory, which frames hope as goal-directed thinking comprising pathways and agency, the researchers found that hope declined significantly in both groups over the treatment period, falling by an average of 1.48 points (p = .003). Hope scores correlated negatively with decision regret (r = -.383, p = .028), meaning that patients whose hope eroded more were more likely to express regret about their treatment choice. Crucially, this decline was universal: it occurred regardless of whether patients completed therapy or stopped early. The authors argue that this pattern warrants psychosocial monitoring for all patients on immunotherapy, not only those who struggle with side effects or discontinue treatment. Hope, in this framing, is not a fixed personality trait but a dynamic clinical variable that can be tracked and potentially supported.

The qualitative interviews added texture that numbers alone could not capture. Treatment-related discomfort was the dominant theme, voiced by 24 of the 33 participants. Financial strain was nearly as pervasive, mentioned by 25 of 33 patients, a finding that echoes a growing international literature on financial toxicity, the term coined to describe how out-of-pocket cancer costs cascade into debt, distress and even treatment abandonment. Yet alongside these burdens, hope for disease control persisted in 31 of 33 patients, an almost universal thread of optimism that coexisted with physical and economic hardship. This coexistence challenges any simplistic assumption that suffering extinguishes hope; instead, patients appeared to hold both realities simultaneously, tolerating discomfort because they believed the therapy was keeping their disease in check.

One of the study’s most intriguing findings emerged from the integration of the quantitative and qualitative strands. On the validated regret scale, only three of the 33 patients voiced regret in their interviews, and even in these cases the regret concerned earlier points in the illness course, such as delays in diagnosis or previous treatment choices, rather than the current decision to start immunotherapy. This produced a discordance between measured and voiced regret: the scale detected rising regret among discontinuers, but patients rarely named the current treatment decision as its object. The researchers suggest that regret in this population may be diffuse, attached to the overall cancer journey rather than to a specific choice, or that patients may be reluctant to criticize a therapy that represents their best remaining option. This gap between what instruments measure and what patients say is precisely the kind of insight that mixed-methods designs are built to expose.

The clinical implications are direct. The authors conclude that pre-treatment counselling for hepatocellular carcinoma patients considering immunotherapy-targeted combinations should be honest and informative rather than merely reassuring. More than one in three patients in this real-world cohort stopped treatment early, and those who did faced worse fatigue, declining quality of life and greater regret. Counselling that prepares patients for the realistic possibility of discontinuation, that discusses financial burden openly, and that normalizes the ebb and flow of hope may better equip patients for whichever trajectory they follow. The finding that discontinuation marks a psychological inflection point also argues for proactive supportive care at the moment treatment stops, rather than waiting for distress to become visible.

The study’s limitations deserve equal attention. With 33 participants from a single medical center, the sample is small, and the authors themselves describe the predictors of regret as hypothesis-generating rather than definitive. The within-group rise in regret among discontinuers did not reach conventional statistical significance, and the between-group comparison, while significant, rests on a modest number of patients. Generalizability beyond the Taiwanese context, with its particular healthcare financing system and hepatitis B-dominated epidemiology, remains to be established. Still, the prospective longitudinal design, the use of validated instruments and the systematic integration of interviews with survey data give the findings a credibility that cross-sectional patient surveys often lack.

What the study ultimately offers is a more complete vocabulary for evaluating cancer treatment. Tumor response rates and overall survival curves will always anchor oncology, but as immunotherapy extends lives, the quality of those lives, and the emotional meaning patients attach to their decisions, become inseparable from treatment success. For hepatocellular carcinoma, a cancer that still claims hundreds of thousands of lives each year globally, the message from Taipei is that hope deserves monitoring as attentively as any biomarker, that the decision to stop therapy deserves psychological support as much as the decision to start, and that honest conversation before the first infusion may be one of the most powerful interventions a care team can deliver.

Subject of Research: Patient-reported hope, decision regret and quality of life during first-line immunotherapy-targeted therapy for hepatocellular carcinoma

Article Title: Beyond tumor response: hope and decision regret during immunotherapy for hepatocellular carcinoma

Article References: Wang, H.-S., Cheng, A.-L., Chen, J.-H., & Huang, T.-W. (2026). Beyond tumor response: hope and decision regret during immunotherapy for hepatocellular carcinoma. Supportive Care in Cancer, 34(10), Article 992. https://doi.org/10.1007/s00520-026-11228-2

Image Credits: AI Generated

DOI: 10.1007/s00520-026-11228-2

Keywords: hepatocellular carcinoma, immunotherapy, decision regret, hope, patient-reported outcomes, quality of life, fatigue, mixed methods, supportive care, financial toxicity, liver cancer, taiwan